title: Molecular basis for atovaquone binding to the cytochrome bc1 complex.
abstract: Atovaquone is a substituted 2-hydroxynaphthoquinone that is used therapeutically to treat Plasmodium falciparum malaria, Pneumocystis carinii pneumonia, and Toxoplasma gondii toxoplasmosis. It is thought to act on these organisms by inhibiting the cytochrome bc1 complex. We have examined the interaction of atovaquone with the bc1 complex isolated from Saccharomyces cerevisiae, a surrogate, nonpathogenic fungus. Atovaquone inhibits the bc1 complex competitively with apparent Ki = 9 nm, raises the midpoint potential of the Rieske iron-sulfur protein from 285 to 385 mV, and shifts the g values in the EPR spectrum of the Rieske center. These results indicate that atovaquone binds to the ubiquinol oxidation pocket of the bc1 complex, where it interacts with the Rieske iron-sulfur protein. A computed energy-minimized structure for atovaquone liganded to the yeast bc1 complex suggests that a phenylalanine at position 275 of cytochrome b in the bovine bc1 complex, as opposed to leucine at the equivalent position in the yeast enzyme, is responsible for the decreased sensitivity of the bovine bc1 complex (Ki = 80 nm) to atovaquone. When a L275F mutation was introduced into the yeast cytochrome b, the sensitivity of the yeast enzyme to atovaquone decreased (Ki = 100 nm) with no loss in activity, confirming that the L275F exchange contributes to the differential sensitivity of these two species to atovaquone. These results provide the first molecular description of how atovaquone binds to the bc1 complex and explain the differential inhibition of the fungal versus mammalian enzymes.
authors.affiliation: Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
authors.forename: Jacques J
authors.initials: JJ
authors.lastname: Kessl
authors.forename: Benjamin B
authors.initials: BB
authors.lastname: Lange
authors.forename: Torsten
authors.initials: T
authors.lastname: Merbitz-Zahradnik
authors.forename: Klaus
authors.initials: K
authors.lastname: Zwicker
authors.forename: Philip
authors.initials: P
authors.lastname: Hill
authors.forename: Brigitte
authors.initials: B
authors.lastname: Meunier
authors.forename: Hildur
authors.initials: H
authors.lastname: Pálsdóttir
authors.forename: Carola
authors.initials: C
authors.lastname: Hunte
authors.forename: Steve
authors.initials: S
authors.lastname: Meshnick
authors.forename: Bernard L
authors.initials: BL
authors.lastname: Trumpower
mesh_terms: D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism; D053626:Atovaquone; D001665:Binding Sites; D001667:Binding, Competitive; D014450:Electron Transport Complex III / Q000737:chemistry* / Q000378:metabolism*; D008969:Molecular Sequence Data; D009285:Naphthoquinones / Q000737:chemistry* / Q000378:metabolism*; D010084:Oxidation-Reduction; D011090:Polyenes / Q000737:chemistry / Q000378:metabolism; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D012441:Saccharomyces cerevisiae; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D009285:Naphthoquinones; D011090:Polyenes; D014451:Ubiquinone; C041573:stigmatellin; D014450:Electron Transport Complex III; C003741:ubiquinol; D053626:Atovaquone